# Wall Street's Wildest Showdowns: Bulls vs. Bears! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-10-01T00:09:00.636Z Source: https://newsyai.com/edition/6944e42c-5a58-451c-9462-bf208f01992b Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Wall Street's Most Polarizing Shitshows: 3 Stocks Where Bulls and Bears Are Throwing Hands (and Maybe Some Feces) — Fresh Edition, October 1, 2026** Futures mixed—Dow flat, Nasdaq mainlining the AI hype like it's the fountain of youth, crude oil bouncing like a caffeinated squirrel on a trampoline. Last round's robot delivery flops, enterprise AI restructurings, and solar debt hangovers? Yesterday's news. These three tickers have the Street more divided than a crypto bro at a family reunion. Sky-high short interest across the board (one hovering ~40%, another ~35%, one ~33% with days-to-cover that scream volatility potential), AI voice tech merger drama, AI drug discovery cash furnaces, and CRISPR gene-editing pipeline moonshots vs. clinical/clinical-hold headaches. Fresh short data, filings, and chatter only—no reruns. Bulls see explosive TAM, platform leverage, and one-time therapies; bears see debt bombs, dilution landmines, and cash incinerators. Then the first-principles hammer drops.[[1]](https://www.chartmill.com/stock/markets/usa/screener/most-shorted-stocks) ### 1. SoundHound AI (SOUN) – Voice AI Rockstar or LivePerson Debt Drag Queen? SOUN carries elevated short interest around 40% of float (~165M shares short as of mid-September 2026 settlement, days-to-cover ~7).[[2]](https://curvedtrading.com/stocks/soun/short-interest/) **Bull Case (The "45% Revenue Ramp, OASYS Platform, and Squeeze Crew")** Bulls highlight rapid revenue growth (Q2 up 45% to ~$62M), AI voice tech momentum in autos/restaurants, the pending LivePerson merger bringing customer scale and OASYS platform upside, analyst targets implying big upside, and short-squeeze fuel if utilization or deal closes beat expectations. Institutional buying and AI tailwinds add momentum vibes.[[3]](https://www.fool.com/investing/2026/09/03/with-nearly-40-short-interest-is-soundhound-stock/) **Bear Case (The "Merger Debt Load, Ongoing Losses, and Dilution Crew")** Bears hammer on the LivePerson deal dragging in declining revenue and debt, persistent unprofitability (adjusted EBITDA negative), risk of future equity raises to clean it up, and questions on whether the economics scale amid competition. Short interest captures bets the voice AI story is hype masking a money pit.[[3]](https://www.fool.com/investing/2026/09/03/with-nearly-40-short-interest-is-soundhound-stock/) **My First-Principles Take**: Voice AI value accrues to platforms with sticky integrations, high utilization in verticals, and network effects that drive recurring revenue—economics reward real deployment wins over flashy demos. SOUN has genuine tailwinds from automation hunger, but durable profits only come if the merger integrates cleanly, utilization ramps without endless raises, and unit economics beat alternatives. The AI voice bet is directionally powerful amid labor shortages, yet it's an execution-heavy play prone to integration shocks and funding volatility. At these short levels, volatility rocket fuel—catalysts roast bears; stumbles feed the fire. Size responsibly, degenerates. ### 2. Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Unicorn or Cash-Burning Petri Dish? RXRX sports notable short interest around 35% of shares (~178-180M shares short, days-to-cover stretching to ~12-13).[[4]](https://stocknear.com/stocks/RXRX/statistics/short-interest) **Bull Case (The "Platform Scalability, Pipeline Hits, and Efficiency Crew")** Bulls point to the AI-powered drug discovery platform promising faster/cheaper R&D, multiple pipeline candidates, potential for big pharma partnerships or deals, and positioning in the massive pharma TAM where traditional methods are slow and expensive. Some see short-squeeze potential on any positive clinical or partnership print.[[5]](https://www.marketbeat.com/stocks/NASDAQ/RXRX/short-interest/) **Bear Case (The "Heavy Cash Burn, No Approved Drugs, and Clinical Risk Crew")** Bears cite ongoing losses and burn rate, lack of approved products despite years of platform hype, clinical and regulatory hurdles in biotech, and skepticism that the AI angle delivers outsized returns amid competition from bigger players. Short interest reflects bets the story is more sci-fi than substance.[[5]](https://www.marketbeat.com/stocks/NASDAQ/RXRX/short-interest/) **My First-Principles Take**: Drug discovery value accrues to approaches that reliably cut time/cost to viable candidates with measurable clinical success—economics reward validated outputs and capital efficiency over pure platform promises. RXRX has real tailwinds from AI adoption in R&D and a novel approach, but durable profits only come if candidates advance through trials without massive dilution, partnerships materialize at scale, and the platform proves superior to traditional methods. The AI biotech bet is directionally explosive amid innovation demand, yet it's a high-risk, capital-intensive play prone to clinical failures and hype cycles. At these short levels, volatility grenade—positive catalysts roast shorts; weakness feeds the fire. High-risk, high-reward for the bold. ### 3. Intellia Therapeutics (NTLA) – CRISPR One-Shot Gene Editor or Clinical Hold Victim? NTLA carries elevated short interest around 33%+ of float (~46-47M shares short, days-to-cover ~14).[[6]](https://chartexchange.com/symbol/nasdaq-ntla/short-interest/) **Bull Case (The "Priority Review, HAE/ATTR Pipeline, and One-Time Therapy Crew")** Bulls highlight FDA acceptance/priority review for lonvo-z in hereditary angioedema (HAE) with a March 2027 decision date, promising one-time in vivo CRISPR treatments for rare diseases, strong institutional backing (including ARK buys), and potential for significant value creation if trials succeed. Some see short-squeeze potential on positive regulatory or data updates.[[7]](https://kalkine.com/news/healthcare/why-an-fda-decision-could-trigger-a-short-squeeze-in-intellia-therapeutics-nasdaqntla-stock) **Bear Case (The "Clinical Holds, Cash Burn, and Biotech Execution Crew")** Bears cite past clinical holds on trials, heavy cash burn typical of pre-commercial biotechs, risks in gene editing safety/efficacy at scale, and questions on commercialization timelines amid competition. Short interest captures bets the CRISPR hype outpaces near-term delivery.[[8]](https://trendmatrix.com/stocks/NTLA) **My First-Principles Take**: Gene editing value accrues to therapies with clear clinical utility, durable effects, and manageable safety profiles that command premium pricing—economics reward proven outcomes and scalable manufacturing over early promise alone. NTLA has genuine tailwinds from CRISPR breakthroughs and regulatory progress on key programs, but durable profits only come if trials clear hurdles cleanly, manufacturing scales, and reimbursement follows. The gene-editing bet is directionally powerful on unmet medical needs, yet it's a clinical/regulatory-heavy play prone to setbacks and financing volatility. At these short levels, volatility rocket fuel—catalysts roast bears; stumbles feed the fire. There you have it—three fresh brawls proving disagreement is the market's favorite drug. Do your own damn homework, size like an adult, and remember: the tape stays irrational longer than your margin account can breathe. Sources pulled from latest short interest data, filings, and analyst notes as of late September/early October 2026. Trade responsibly, you magnificent animals.